A groundbreaking new dietary approach for managing Crohn's disease has emerged, revealing promising results that could change the way we view treatment options for this condition. Recent research conducted in the United States indicates that patients adhering to a short-term calorie-restricted diet experienced notable improvements in both their physical symptoms and inflammatory biomarkers associated with mild to moderate Crohn’s disease (CD).
The study highlighted that participants following this intermittent restrictive eating plan achieved significantly better rates of clinical response and remission after just three months. Specifically, the diet required them to restrict their caloric intake for only five days each month, which is a manageable commitment for many.
In this controlled clinical trial, 100 participants were randomly assigned to either a fasting mimicking diet (FMD) or their usual dietary habits over the course of three consecutive months. The researchers meticulously compared changes in the Crohn's Disease Activity Index (CDAI) and inflammatory markers between these two groups. Astonishingly, nearly 70% of those in the FMD group met the primary outcome of clinical response, which was defined as a reduction in CDAI of at least 70 points. In stark contrast, less than 44% of the control group achieved similar results.
Furthermore, around 65% of the FMD participants reached clinical remission, characterized by a CDAI score of 150 or lower after completing the third diet cycle, compared to only 38% in the control group. This diet consisted of consuming 700 to 1100 calories daily for five consecutive days, followed by a return to their regular eating patterns for the rest of the month. During the calorie-restricted days, participants were provided with plant-based meals designed to ensure they received adequate nutrition while still maintaining the deficit.
One of the key indicators of inflammation, faecal calprotectin, showed remarkable improvement at the end of the third diet cycle, displaying a mean reduction of 22% in the FMD group, while the control group saw an 8% increase. Notably, nearly 40% of those on the FMD experienced a decline in faecal calprotectin of 50% or more, in contrast to just 6% in the control group.
Additionally, the mean change in C-reactive protein—a marker often used to measure inflammation—showed a 1% reduction in the FMD group compared to a 37% increase in the control group, although this result was close to missing statistical significance (P = 0.06). Interestingly, there was no significant difference observed in the erythrocyte sedimentation rate between the two groups.
Professor Sidhartha Sinha, the study's senior author and assistant professor of gastroenterology and hepatology at Stanford University, expressed his surprise and delight at the positive outcomes: "We were very pleasantly surprised that the majority of patients seemed to benefit from this diet. We noticed that even after just one FMD cycle, there were clinical benefits."
However, the authors noted the challenges inherent in studying dietary interventions, primarily due to the reliance on self-reporting and the difficulty in blinding participants. Despite these challenges, this trial successfully demonstrated declines in objective markers of inflammation alongside improvements in symptoms, providing a strong case for the effectiveness of the FMD.
It's also worth mentioning that less than half of the control group reported improvements in their symptoms. Researchers attribute this to natural fluctuations in Crohn’s disease symptoms and the effectiveness of standard care and medications. After a three-month washout period following the final FMD cycle, clinical responses and remission rates became similar between the two groups, indicating that the optimal frequency of FMD cycles needed for sustained benefits remains uncertain. The researchers suggested that additional cycles may be necessary to maintain these clinical improvements over time.
Participants with mild CD experienced a higher clinical response rate from the FMD compared to the control group (75% vs. 48%), and those with moderate CD also fared better (57% vs. 11%). Moreover, individuals with colonic disease had a greater response rate on the FMD compared to the control diet (82% vs. 33%), as did those with ileocolonic disease (71% vs. 30%). However, those with isolated ileal disease did not exhibit this trend (56% vs. 60%).
Interestingly, the FMD proved to be particularly effective among participants not receiving any medical therapy, with a success rate of 77% compared to 33% in the control group. The average age of participants in the study was 45 years, and about 40% of both groups had a BMI classified as overweight. The control group notably had a higher proportion of individuals with obesity (31% vs. 15%) and included fewer women (56% vs. 80%) than the FMD group.
Throughout the study, there was no significant difference in therapy escalation—such as prescriptions for corticosteroids, initiation of new advanced therapies, or dosage increases—between the two groups (28% for FMD versus 25% for control). While some participants in the FMD group reported experiencing fatigue and headaches during the trial, it is noteworthy that no serious side effects were documented.
This study, published in Nature Medicine on January 13, 2026, opens up exciting discussions about the role of diet in managing Crohn's disease. As we consider these findings, one must ask: Could dietary changes be a viable alternative or complement to traditional treatments for Crohn's? What are your thoughts on the efficacy of such fasting mimicking diets for chronic conditions like Crohn's disease?
